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Abstract
Glycogen synthase kinase 3 (GSK3) plays an important role in the development of diabetes
mellitus and renal injury. GSK3 inhibition increases glucose uptake in insulin-insensitive
muscle and adipose tissue, while it reduces albuminuria and glomerulosclerosis in acute kid-
ney injury. The effect of chronic GSK3 inhibition in diabetic nephropathy is not known. We
tested the effect of lithium, the only clinical GSK3 inhibitor, on the development of diabetes
mellitus and kidney injury in a mouse model of diabetic nephropathy. Twelve-week old
female BTBR-ob/ob mice were treated for 12 weeks with 0, 10 and 40 mmol LiCl/kg after
which the development of diabetes and diabetic nephropathy were analysed. In comparison
to BTBR-WT mice, ob/ob mice demonstrated elevated bodyweight, increased blood glu-
cose/insulin levels, urinary albumin and immunoglobulin G levels, glomerulosclerosis,
reduced nephrin abundance and a damaged proximal tubule brush border. The lithium-10
and -40 diets did not affect body weight and resulted in blood lithium levels of respectively
<0.25 mM and 0.48 mM. The Li-40 diet fully rescued the elevated non-fasting blood glucose
levels. Importantly, glomerular filtration rate was not affected by lithium, while urine albumin
and immunoglobulin G content were further elevated. While lithium did not worsen the glo-
merulosclerosis, proximal tubule function seemed affected by lithium, as urinary NGAL lev-
els were significantly increased. These results demonstrate that lithium attenuates non-
fasting blood glucose levels in diabetic mice, but aggravates urinary albumin and immuno-
globulin G content, possibly resulting from proximal tubule dysfunction.
Introduction
Diabetes mellitus (DM) often leads to diabetic nephropathy, a progressive decline in kidney
function. Diabetic nephropathy starts with hypertrophy of renal proximal tubules and hyperfil-
tration.[1] Release of growth factors, cytokines and pro-inflammatory markers consequently
leads to oxidative stress, manifesting as tubular atrophy and interstitial fibrosis.[2–4] A silent
phase follows, as the glomerular filtration rate (GFR) turns back to normal.[5] After this
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period, a progressive decline in GFR, and thus kidney function, develops.[6, 7] This decline in
renal function is histopathologically characterized by a substantial thickened glomerular base-
ment membrane (GBM), increased diffuse or nodular glomerulosclerosis, hyaline arterioscle-
rosis, tubulointerstitial fibrosis and tubulointerstitial atrophy.[8] Diabetic nephropathy is
diagnosed via standard criteria for chronic kidney disease (CKD): a GFR below 60 mL/min/
1.73m2 and/or more than 30mg albumin/g creatinine in urine.[9–11] The high impact of diabe-
tes as a cause for kidney disease is illustrated by the fact that 25–40% of all patients who have
DM for 20–25 years eventually develop CKD.[12] Due to the large incidence of DM, ~43% of
all patients with end-stage renal disease is caused by DM and this is expected to increase, as the
World Health Organization recently reported that the prevalence of diabetes quadrupled
between 1980 and 2014.[10, 13, 14]
The serine/tyrosine kinase glycogen synthase kinase 3 (GSK3) has been shown to play a
prominent role in cellular glucose uptake and storage. In healthy individuals, glucose uptake is
stimulated by binding of insulin to its receptor, as this activates the insulin receptor substrate-
1 (IRS-1), PI3-kinase and Akt, which subsequently enhances the plasma membrane abundance
of glucose transporter type 4 (GLUT4) therewith increasing cellular glucose uptake.[15, 16]
Glucose storage is also activated by Akt, as it stimulates glycogen synthase activity leading to
intracellular glucose storage in the form of glycogen.[17, 18] As GSK3 inhibits both IRS-1 and
glycogen synthase, it attenuates cellular glucose uptake and glycogen storage.[15, 16, 19, 20] As
a consequence, it has been thought that GSK3 inhibition could be beneficial in DM. Indeed,
GSK3 activity/abundance was elevated in various tissues of diabetic animals and patients[21–
23] and GSK3 inhibition or haplo-insufficiency reduced insulin resistance and blood glucose
levels in diabetic mice.[24–26]
Interestingly, recent studies indicated that moderate GSK3 inhibition is also beneficial in
the prevention and treatment of acute kidney injury (AKI). Firstly, inhibition of GSK3β in
murine models of cisplatin- and ischemia/reperfusion-induced AKI boosted cell proliferation
and the repair machinery of renal tubular epithelia, which coincided with increased levels of
cyclinD1, c-Myc and HIF-1α.[27, 28] Secondly, GSK3 inhibition in LPS or Adriamycin-
induced AKI decreased pro-inflammatory signalling and attenuated glomerular damage.[29]
Lastly, GSK3 inhibitors decreased ROS-dependent apoptosis of renal epithelial cells in rodents
with paraquat-induced AKI.[30] In agreement with these findings, mice overexpressing a
GSK3 variant, mediating resistance to inhibition by Akt, demonstrated albuminuria and glo-
merulosclerosis.[31] Altogether, these data indicated that GSK3 inhibition attenuates proximal
tubule and glomerular damage.
Considering the beneficial effects of GSK3 inhibition in DM and renal injury, we hypothe-
sized that GSK3 inhibition may attenuate development of diabetic nephropathy. The only clin-
ically available GSK3 inhibitor is lithium, which inhibits GSK3 in a direct and indirect
manner, by respectively acting as a competitor for Mg2+ binding,[23] which is required for
substrate phosphorylation, and by promoting its phosphorylation of GSK3α and GSK3β at ser-
ine 21 or 9, respectively, resulting in their inactivation.[20] In clinics, lithium is used to treat
patients with bipolar disorder in order to prevent episodes of mania using a daily dose of 900–
1800 mg.[27, 32] It has been shown that this lithium dose leads in some patients to the devel-
opment of kidney damage.[27, 33] Importantly, however, Hu et al demonstrated that a sub-
clinical daily dose of 100 mg lithium already suffices to reduce non-fasting blood glucose levels
in diabetic patients.[34]
Therefore, we here investigated the effect of subclinical lithium doses on the development
of diabetic nephropathy. For this, we used BTBR-ob/ob mice, a widely-accepted DM type 2
(DM2) model, as, due to a homozygous ob/ob mutation inducing leptin deficiency, these mice
consume excessive amount of food, and develop obesity and diabetes. Importantly, the BTBR-
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ob/ob mice develop signs of both early and advanced human diabetic nephropathy, as they
exhibit albuminuria at an age of 4 weeks and morphological glomerular lesions at an age of 8
weeks.[11]
Materials and methods
Animal model
Twelve-week old female wild-type and ob/ob BTBR T+ Itpr3tf/J (BTBR) mice were obtained
from The Jackson Laboratory. Mice were housed at The Jackson Laboratory in a temperature-
controlled room with a 12:12h light-dark cycle and had ad libitum access to water and food
(standard chow (7013, NIH-31 Modified) or standard chow supplemented with respectively
10 and 40 mmol lithiumchloride (LiCl)/kg chow, Harlan Laboratories Inc, Madison, WI,
USA). Immediately before sacrifice by cervical dislocation, which took place a few hours after
initiation of the light cycle, blood was collected via submandibular bleeding. Kidneys were col-
lected and processed for histology or immunoblotting, as described.[35] Animal studies were
approved by The Jackson Laboratory’s Institutional Animal Care and Use Committee.
GFR determination
GFR was determined using the FITC-Inulin clearance method.[36] At week 11, mice received
a single bolus injection of dialysed FITC-inulin. Before FITC-inulin injection, blood was col-
lected to determine baseline fluorescence. At 3, 5, 7, 10, 15, 35, 56, and 75 minutes after injec-
tion, blood was collected via the tail. Blood fluorescence was determined using a Cytofluor II
Fluorescence Multiwell Plate Reader (PerSeptive Biosystems) with 485nm excitation and
538nm emission. Renal excretion rate of inulin was determined based on the decay fluores-
cence counts over time. Based on this excretion rate, the GFR was determined.
Glucose tolerance test
At 10 weeks, a glucose tolerance test was performed. After a 4-hour fast, mice received an
intraperitoneal injection of 2 mg/g body weight glucose. Before and at 15, 30, 60 and 120 min-
utes after injection, blood was collected from the tail and glucose levels were immediately
determined with a blood glucose meter (OneTouch Ultra12). Before sacrifice, blood was col-
lected by submandibular bleeding and non-fasting glucose levels were immediately deter-
mined using the blood glucose meter.
Blood and urine analysis
Blood was centrifuged at 3000xg for 5 minutes to separate serum from blood cells. Serum con-
centration of lithium was measured using The Medimate Mini-Lab (Enschede, The Nether-
lands). Insulin concentration in serum was measured using Ultra Sensitive Insulin ELISA
(Cristal Chemical Inc.). Additional serum analyses of blood urea nitrogen (BUN) and neutro-
phil gelatinase associated lipocalin-2 (NGAL) were performed using the NCal NIST-Calibrated
Kit (ARBOR ASSAYS) and Mouse-NGAL DuoSet Kit (RnD Systems) respectively. Urine was
analysed for creatinine and albumin on a Beckman Synchron CX5 Chemistry Analyzer (Ful-
lerton, CA, USA) by the Histology department of The Jackson Laboratory, as described[37],
while urinary IgG levels were determined with the Mouse-IgG ELISA (Roche, V.10), and
NAG-activity with NAG Activity Assay Kit (Abcam).
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Histology
Kidney were isolated and stored in 3.5% PFA solution. After fixation for two days, kidneys
were embedded in paraffin. Kidney slides were stained with Periodic acid-Schiff or Picro Sirius
Red. Assessment of the slides was performed using blind randomization.
Immunoblotting
Immunoblotting was performed as described[38]. Primary antibodies included rabbit anti-
cubilin and sheep anti-megalin (gifts from Prof. Pierre Verroust, INSERM, Paris, France),
mouse anti-GSK3β (#610201, BD Biosciences), rabbit anti-pGSK3β (#9336S, Cell Signalling
Technology) and guinea pig anti-nephrin (#20R-NP002, Fitzgerald Industries International).
Proteins were visualized using enhanced chemiluminescence (Pierce) and the “ChemiDoc
XRS” (Bio-Rad). For semi-quantification the QuantityOne software (Bio-Rad) was used, while
Coomassie blue staining was used to determine and correct for total protein input.
RNA isolation, primer design and reverse transcription-quantitative PCR
(RT-qPCR)
RNA from renal cortex was isolated using TRIzol1 (Gibco Life Technologies, Rockville, MD,
USA) and 1.5 μg of RNA was reverse transcribed using the Moloney murine leukemia virus
reverse transcriptase kit (Promega, Madison, WI, USA), according to the suppliers’ protocol.
Following a 10-fold dilution, mRNA levels were assessed by RT-qPCR using SYBR-green
(Applied Biosystems, Foster City, CA, USA) and normalized to housekeeping gene Rplp0
(36B4). Primer sequences were as listed in S1 Table.
Statistical analysis
All statistical analyses were performed in GraphPad Prism. Statistical analyses were performed
using one-way ANOVA with Bonferroni correction. Differences were considered significant
at p<0.05. Data are presented as means and SEMs.
Results
GSK3 activity is increased in kidneys of ob/ob mice
Diabetic animals and patients demonstrated an increased abundance or decreased phosphory-
lation of GSK, indicative of an increased activity.[21–23] As overexpression of active GSK3
caused albuminuria and glomerulosclerosis,[31] we first wanted to establish whether GSK3
activity was altered in 24-week old BTBR-ob/ob mice, as at this age these mice demonstrate
diabetes, albuminuria and glomerular damage.[11] Using whole kidney homogenates of 24
week-old BTBR-wild type (WT) and BTBR-ob/ob mice, total and phosphorylated GSK3 abun-
dance was examined by immunoblotting (Fig 1A and 1B). Semi-quantification demonstrated
that total GSK3 abundance was not different between both groups, but that the pGSK3/GSK3
ratio was significantly decreased in BTBR-ob/ob mice, suggesting that diabetes caused GSK3
overactivity in the kidneys of these mice (Fig 1C).
Lithium reduces non-fasting blood glucose levels in ob/ob mice
To determine whether the GSK3 inhibitor lithium might constitute a treatment for diabetic
nephropathy, we wanted to test the effect of lithium at a point in which early signs of diabetic
nephropathy were already observed. In line with data from others,[11] our 12 weeks old
BTBR-ob/ob mice demonstrated an increased body weight (53.6 vs 28.1 g, p<0.05) and
Lithium in diabetic nephropathy
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elevated albumin creatinine ratio (ACR) as compared to WT mice (101.8 vs 12.0 mg/g,
p<0.05). After randomizing for body weight and ACR, the ob/ob BTBR mice received standard
chow (control) or chow supplemented with 10 (Li-10) or 40 (Li-40) mmol LiCl per kg food for
12 weeks (Table 1). As a control for obesity/DM2 development in ob/ob BTBR mice, an addi-
tional group of WT mice only received standard chow. The Li-10 and -40 diets did not affect
body weight and led to serum lithium levels of<0.25 mM and 0.48 ± 0.04 mM, respectively
(Table 1). These levels are subclinical as in bipolar patients a range of 0.6–1.0 mM is
maintained.
To determine the effect of lithium on DM2 itself, a glucose tolerance test was performed
after 10 weeks of lithium treatment. Following fasting for 4 hours, blood glucose levels were
increased in the ob/ob mice, which were not affected by lithium (Fig 2A). Then, following an
intraperitoneal glucose injection, the mice were subjected to a glucose tolerance test. At 15
minutes after injection, blood glucose levels were strongly elevated in the ob/ob mice as com-
pared to WT controls, while lithium attenuated this elevation (Fig 2A). Notably, blood glucose
levels in ob/ob mice at 30, 60 and 120 minutes were mostly above the upper detection limit of
the glucose meter (S2 Table), precluding further information. At the time of sacrifice, non-
Fig 1. pGSK3/GSK3 ratio in BTBR-WT and ob/ob mice. Kidneys from 24-week old female BTBR-WT and
-ob/ob mice were isolated and protein lysates were immunoblotted for pGSK3 and GSK3. Representative
immunoblots for WT and ob/ob mice for (A) GSK3 and (B) pGSK3 are depicted. Corresponding densitometric
analysis of (C) total GSK3 abundance and (D) pGSK3/GSK3 ratio (n = 9 per group). **p<0.01. Cm,
Coomassie.
https://doi.org/10.1371/journal.pone.0189485.g001
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fasting blood glucose levels were determined. Ob/ob mice also exhibited elevated non-fasting
blood glucose, which was reduced in the lithium-treated mice (Fig 2B). In fact, blood glucose
levels of the ob/ob mice on Li-40 diet were similar to those of the WT controls. In line with an
increased glucose uptake and tolerance with GSK inhibition, the non-fasting insulin levels
were elevated in ob/ob mice as compared to WT mice, and tended to decrease (p = 0.14) in the
mice on the Li-40 diet (Fig 2C).
Table 1. Body weight and lithium levels.
Group Bodyweight (g) Lithium (mM)
Week 0 Week 6 Week 12 Week 12
WT 28.1 ± 0.6 32.3 ± 0.9 35.5 ± 1.3 ND
ob/ob 53.6 ± 1.3*** 73.4 ± 1.3*** 83.5 ± 2.4*** ND
ob/ob Li-10 54.3 ± 1.8 71.7 ± 2.0 79.2 ± 3.0 <0.25
ob/ob Li-40 53.8 ± 1.5 72.4 ± 1.9 78.7 ±2.0 0.48 ± 0.04
12-week old female BTBR-WT and -ob/ob mice received standard chow or chow with lithium supplementation (10 or 40 LiCl/kg) for 12 weeks. Lower
detection range of the lithium analyser was 0.25 mM.
***p<0.001 vs. WT.
ND, not determined.
https://doi.org/10.1371/journal.pone.0189485.t001
Fig 2. The effect of lithium on blood glucose and insulin levels. 12-week old female BTBR-WT and -ob/ob
mice received standard chow or chow with lithium supplementation (10 or 40 mmol LiCl/kg) for 12 weeks. Two
weeks before sacrifice, mice were fasted for 4 hours, after which they received an intraperitoneal injection of 2
mg glucose/g bodyweight. Blood was collected before and 15 minutes after injection and blood glucose levels
were determined (A). At the time of sacrifice blood was collected to analyze non-fasting (B) glucose and (C)
insulin levels, n = 9 per group. *p<0.05; **p<0.01; ***p<0.001.
https://doi.org/10.1371/journal.pone.0189485.g002
Lithium in diabetic nephropathy
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Lithium increases urinary albumin and IgG content in BTBR-ob/ob mice
To establish the effect of lithium on diabetic nephropathy, we analysed the mice for GFR by
inulin clearance, blood urea nitrogen (BUN) and ACR. After correction for bodyweight,
thereby correcting for differences in kidney size,[39] GFR was not statistically different
between the four groups (Fig 3A). There was also no significant difference in BUN between
the groups, although it tended to increase in the ob/ob mice (p = 0.15) and tended to attenuate
again with lithium (p = 0.42) (Fig 3B). ACR, determined from spot urine isolated at 12 weeks
of treatment, was elevated in ob/ob-Ctr mice compared to WT mice. Importantly, lithium
treatment increased ACR, which was significant in the Li-40 diet group (Fig 3C). Finally, spot
urine was also analysed for the presence of immunoglobulin G (IgG), which is only found in
urine when the filtration barrier is damaged.[40, 41] Urinary IgG levels were significantly
increased in ob/ob mice as compared to WT controls, which were aggravated by both the Li-10
and Li-40 diet (Fig 3D).
Lithium-induced aggravation of albuminuria is likely not caused by
glomerular damage
Both albumin and IgG levels are elevated in the urine of ob/ob-Ctr mice as compared to WT
mice, indicating that the glomerular filtration barrier is damaged in the obese mice. The
Fig 3. The effect of lithium on GFR, BUN, and urinary albumin and IgG levels. 12-week old female
BTBR-WT and -ob/ob mice received standard chow or chow with lithium supplementation (10 or 40 mmol LiCl/
kg) for 12 weeks. After 11 weeks of treatment, mice received a FITC-inulin bolus injection. Inulin clearance
was determined via the decay of FITC-inulin in blood (A). At the time of sacrifice, blood was isolated and BUN
was determined (B), while spot urine was collected earlier that week to determine (C) albumin-creatinine ratio
and (D) IgG content, n = 9 per group. *p<0.05; ***p<0.001; ACR, albumin-creatinine ratio.
https://doi.org/10.1371/journal.pone.0189485.g003
Lithium in diabetic nephropathy
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further elevation of urinary albumin and IgG levels upon lithium treatment might be due to
further deterioration of glomerular function, but might also result from injury to the proximal
tubule, as both albumin and IgG are reabsorbed by the proximal tubules following filtration
leakage.[42] To investigate the origin of the increased urinary albumin and IgG levels in the
lithium treated ob/ob mice, we first assessed the extent of mesangial matrix expansion using
PAS staining (Fig 4A–4C). In line with the elevated urinary albumin and IgG levels, ob/ob-Ctr
mice demonstrated significantly more glomeruli with moderate and severe mesangial matrix
expansion as compared to WT mice (Fig 4D and 4E). Interestingly, the number of moderately-
affected glomeruli was reduced in the Li-40 group, while no significant differences were found
with the other groups (Fig 4D and 4E). To obtain additional information on the abundance of
podocytes, which form the filtration barrier, we next analysed our kidney samples for mRNA
and protein levels of proteins that are characteristic for podocytes. However, podocin, nephrin,
synaptopodin and podoplanin mRNAs levels were not affected by lithium (S1 Fig). Moreover,
immunoblotting revealed that the abundance of nephrin was significantly reduced in the ob/
ob-Ctr mice as compared to WT mice, which seemed to reverse in the Li-40 group, but this
was not significant (p = 0.33) (Fig 4F and 4G). The nephrin immunoblotting was specific,
because only one band around the predicted mass (180 kDa) was detected, which was observed
in samples derived from the cortex, but not medulla (S2 Fig).
Lithium may affect proximal tubular function
As proximal tubules reabsorb both albumin and IgG[43] in case of a damaged renal filter, we
also tested whether dysfunction of this segment due to lithium may have caused the elevated
urinary albumin and IgG levels observed with lithium. However, immunoblotting for megalin
Fig 4. Analysis of glomerular injury upon lithium treatment. 12-week old female BTBR-WT and -ob/ob mice received standard chow or chow with lithium
supplementation (10 or 40 LiCl mmol/kg) for 12 weeks. After sacrifice, kidneys were isolated and the absence (A) or presence of moderate (B) or severe (C)
mesangial matrix expansion was determined using PAS staining. Moderate and severe mesangial matrix expansion was defined as an increased presence of
mesangial matrix (indicated by stars) with the moderate form still having some open capillary lumens (indicated by arrows) while these are basically absent in
the severe form. Scale bar indicates 10 μM. The percentage of glomeruli with moderate or severe mesangial matrix expansion was scored as follows: 0)
0–1%, 1) 1–5%, 2) 5–20%, 3) 20–50%, 4) >50% (D and E), n = 9 per group. Kidney lysates were used to determine nephrin abundance via immunoblotting
(F) and subsequent semi-quantification (G), n = 9 per group. *p<0.05; ***p<0.001. Cm, Coomassie.
https://doi.org/10.1371/journal.pone.0189485.g004
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and cubilin, which are essential for albumin reabsorption in proximal tubules, revealed no dif-
ferences between control and lithium-treated ob/ob mice (Fig 5A and 5B). To further investi-
gate potential lithium-induced damage to the proximal tubule, we analysed the urinary activity
and abundance of two different proximal tubule damage markers, being N-Acetylglucosamini-
dase (NAG) and serum neutrophil gelatinase associated lipocalin-2 (NGAL), respectively.
While urinary NAG activity was not different between the groups (Fig 5C), urinary NGAL lev-
els were significantly elevated by lithium (Fig 5D). Finally, the proximal brush border was
stained using periodic acid-Schiff (PAS), as its disappearance indicates proximal tubule dam-
age, as also found in early stages of diabetic nephropathy[44, 45]. In ob/ob mice the number of
renal tubular epithelia with a reduced PAS staining in the brush border was increased as com-
pared to WT mice, which was not significantly affected by lithium (Fig 5E and 5F). Finally, we
performed some additional analyses to better understand the effects of lithium application in
diabetic nephropathy. Using Picro Sirius Red staining, interstitial fibrosis was scored as absent,
minimal or mild (S3A–S3C Fig). No differences were found between groups (S3D Fig). Fur-
thermore, cortical mRNA levels of αSMA, CTGF, TGFβ and different inflammation markers
were assessed. While no significant differences were found for the various inflammatory mark-
ers (S4 Fig), lithium partially reversed CTGF mRNA levels, but did not significantly reduce the
increased αSMA levels in the ob/ob-Ctr mice, as compared to WT (Fig 6). No significant dif-
ferences were found in TGFβ mRNA levels (Fig 6).
Discussion
Lithium reduces blood glucose levels via mechanisms likely involving
insulin signaling
This study demonstrated that low lithium doses attenuate non-fasting blood glucose in
BTBR-ob/ob mice, while fasting blood glucose was not affected. These low lithium doses
(10 and 40 mmol/kg food) resulted in blood lithium levels of respectively <0.25 mM and
0.48 mM, which are both below the clinically used blood lithium concentration used to treat
bipolar patients (0.6–1.0 mM). Interestingly, daily administration of 100 mg of lithium car-
bonate in diabetic patients, which is a ~10-fold lower dose as normally administered to
bipolar patients, also caused a reduction in postprandial blood glucose levels, while fasting
blood glucose levels were not affected.[34] In agreement, other studies demonstrate that the
beneficial effect of lithium on blood glucose handling only occurs in presence of insulin.[34,
46] The precise mechanism by which lithium reduces blood glucose handling was not inves-
tigated in these studies although it likely involves its effect on GSK3 activity and subsequent
regulation of IRS-1 and glycogen synthase. Thus, lithium likely enhances the efficacy of
insulin during insulin resistance.[46, 47] This lithium-insulin connection might explain
why in our mouse study and in these diabetic patients lithium decreases blood glucose levels
only in non-fasting conditions. In the latter situation, insulin levels are very low, as blood
glucose levels are maintained via glycogenolysis, in which glucose is formed from glycogen.
[48]
Lithium does not affect GFR in BTBR-ob/ob mice
To determine the effect of lithium on kidney injury in our diabetic mice, we first measured
GFR, as this is also used to diagnose diabetic nephropathy in patients. For this, we assessed
FITC-inulin clearance, as creatinine clearance is not a valid marker for GFR in mice.[49] Strik-
ingly, the GFR of 24-week-old BTBR-ob/ob mice was similar to WT mice, despite overt glo-
merulosclerosis and albuminuria in the ob/ob mice. Also, both lithium diets did not affect
Lithium in diabetic nephropathy
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GFR. It must be noted though, that GFR was calculated as inulin clearance per gram body
weight, although other studies report GFR without correcting for body weight or by correcting
for kidney weight.[36, 50] As kidney weight was not determined by us, but has previously been
shown to be increased by ~2-fold in BTBR-ob/ob mice as compared to WT mice,[39] we
choose to correct for bodyweight, which was increased by 2.3 fold. Moreover, BUN levels were
not statistically different between the groups but tended to increase in the ob/ob mice as com-
pared to WT mice. These findings are in agreement with our GFR correction for bodyweight,
as in comparison to WT mice, the ob/ob mice would have a hyperfiltration if not corrected for
body weight, which would not be in agreement with their BUN levels. Altogether, it is likely
that GFR is not yet affected in 24-week-old female BTBR-ob/ob mice, suggesting that this
model represents a relative early stage of diabetic nephropathy in which a pronounced GFR
decline is not yet present.
Lithium aggravates urinary albumin and IgG content in mice with diabetic
nephropathy
As found previously, BTBR-ob/ob mice exhibited elevated urine albumin levels as compared to
WT BTBR mice.[11] Additionally, we identified that the urine of the ob/ob mice contained sig-
nificantly higher levels of IgG, indicating glomerular damage, as IgG is normally not filtered
by the glomerulus.[40, 41] Lithium further aggravated the urinary content of albumin and
IgG. As both albumin and IgG are normally reabsorbed in the proximal tubule in case of filtra-
tion damage, this aggravation can result from deterioration of proximal tubule or glomerular
function.[42] The latter did not seem affected, as the enhanced mesangial matrix expansion in
the BTBR-ob/ob mice was decreased by lithium and the reduced nephrin abundance in the ob/
ob mice was not further reduced by lithium, but even tended to be attenuated. Furthermore,
mRNA levels of the typical podocyte proteins nephrin, podocin, podoplanin and synaptopodin
were unchanged with lithium. Despite the absence of any indication of lithium-induced glo-
merular injury, we also did not yield strong evidence that lithium caused proximal tubule
injury, as the protein abundance of megalin and cubilin, the receptors responsible for albumin
uptake,[42] were not affected by lithium treatment. Moreover, NAG activity, a marker for
proximal tubule injury, was also not significantly affected by lithium, although it tended to
increase. Only urinary NGAL content was significantly elevated by lithium. Altogether, there
is no strong evidence that lithium caused glomerular injury. As proximal tubule seemed to
exhibit a little more damage in the lithium groups, the increased urinary albumin and IgG con-
tent most likely originates from proximal tubule injury. Although current results are not suffi-
cient to establish the location of damage, a lithium-induced injury of proximal tubules would
be more in line with data obtained in studies analysing the renotoxic effects of clinical lithium
administration. Lithium-treated bipolar patients with CKD are characterized by the presence
of tubular atrophy and interstitial fibrosis, while only a smaller part demonstrates glomerulo-
sclerosis.[51] Also in rabbits it has been shown that lithium first causes tubular atrophy and
Fig 5. Analysis of proximal tubule injury upon lithium treatment. 12-week old female BTBR-WT and -ob/
ob mice received standard chow or chow with lithium supplementation (10 or 40 LiCl/kg) for 12 weeks. Kidney
lysates were used to immunoblot for megalin (A) and cubilin (B) abundance, as shown by representative
images in the upper panels, and subsequent densitometric analysis in lower panels (n = 9/group). Arrows
indicate the 600-kDa bands for megalin and 460-kDa band for cubilin. Spot urine, collected in the week before
sacrifice, was used to determine NAG activity (C) and NGAL (D) levels. Kidney sections were stained with
PAS to determine brush border damage in the different groups, as is shown in the representative pictures (E).
The scale bar represents 50 μM. The presence of brush border damage was scored as follows: 0) none, 1)
minimal, 2) mild, 3) moderate and 4) severe (F). *p<0.05; ***p<0.001. Cm, Coomassie.
https://doi.org/10.1371/journal.pone.0189485.g005
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interstitial fibrosis, while glomerulosclerosis develops much later in disease.[52] Altogether,
our data indicate that administration of subclinical lithium dosi is likely not a good strategy to
combat diabetic nephropathy.
Fig 6. The effect of lithium on cortical αSMA, CTGF and TGFβmRNA levels. 12-week old female
BTBR-WT and -ob/ob mice received standard chow or chow with lithium supplementation (10 or 40 LiCl/kg)
for 12 weeks. After RNA isolation from cortex, mRNA levels of (A) αSMA, (B) CTGF and (C) TGFβwere
determined by qPCR using 36B4 as a housekeeping gene. *p<0.05; **p<0.01.
https://doi.org/10.1371/journal.pone.0189485.g006
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Molecular mechanism underlying lithium-induced albuminuria remains
elusive
We found that lithium increased urine albumin and IgG levels, however the molecular mecha-
nism behind these observations was not identified. Most likely these effects of lithium involve
GSK3 inhibition. It is known that GKS3 plays an important role in the function of proximal
tubules and podocytes,[53, 54] the most likely origins for albuminuria. By inhibiting GSK3,
lithium might have directly affected the function of these cells. We found however that lithium
did not increase GSK3 phosphorylation, an inhibitory modulation, in whole kidney lysates (S5
Fig). As such, lithium-induced albuminuria is most likely due to the direct inhibition of GSK3
by lithium via its competition for magnesium[23]. Alternatively, the increased urine albumin
and IgG levels might be the consequence of the effects of lithium on blood glucose or insulin
levels. While altered blood glucose levels affect both the glomerulus and proximal tubules,
altered insulin levels would mainly affect podocyte function, as insulin receptors are present
on these cells and were shown to play a role in filtration.[39] A role for direct GSK3 inhibition
is however more likely as reduced blood glucose and insulin levels, as observed in this study,
would rather lead to a reduction in albuminuria.[39] Future studies should aim to elucidate
the molecular effects of lithium by analyzing the molecular effects in specific cell types of the
kidney.
The application of lithium in bipolar patients with diabetes mellitus
Thus, although lithium is not likely to become a treatment for diabetic nephropathy, there are
thousands of bipolar patients with DM who are treated with lithium for their bipolar disease.
The precise effect of such higher lithium dose on kidney function in this subpopulation is not
known, however a recent large retrospective analysis did not find an increased risk of CKD,
determined by a decrease in eGFR, in lithium-using patients with DM as compared with lith-
ium only.[55] However, the number of DM patients was rather small. Therefore, it would be
worthwhile to compare renal decline in DM patients who are treated with lithium with those
who are treated with other treatments for mental disease.
Supporting information
S1 Fig. The effect of lithium on mRNA levels of nephrin, podocin, podoplanin and synap-
topodin. 12-week old female BTBR-WT and -ob/ob mice received standard chow or chow
with lithium supplementation (10 or 40 LiCl/kg) for 12 weeks. After RNA isolation from cor-
tex, mRNA levels of nephrin, podocin, podoplanin and synaptopodin were determined by
qPCR using 36B4 as a housekeeping gene. p<0.05.
(PDF)
S2 Fig. The abundance of nephrin in rat cortex and outer medulla. Cortex and medullary
material from 3-month old Wistar rats were immunoblotted for nephrin. Cm, Coomassie.
(PDF)
S3 Fig. The effect of lithium on interstitial fibrosis in BTBR-ob/ob mice. 12-week old
female BTBR-WT and -ob/ob mice received standard chow or chow with lithium supplemen-
tation (10 or 40 LiCl mmol/kg) for 12 weeks. After sacrifice, kidneys were isolated and the
absence (A) or presence of minimal (B) or mild (C) interstitial fibrosis was determined using
Picro Sirius Red staining and (D) scored with respective scores of 0, 1 or 2. Minimal interstitial
fibrosis was defined as the presence of fibrotic tissue in up to 20% of whole kidney. When this
presence exceeded 20%, but was less than 40%, it was defined as mild. In none of the kidneys
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the presence of interstitial fibrosis extended 40% of the whole area.
(PDF)
S4 Fig. The effect of lithium on mRNA expression on various inflammatory markers.
12-week old female BTBR-WT and -ob/ob mice received standard chow or chow with lithium
supplementation (10 or 40 LiCl/kg) for 12 weeks. After RNA isolation from cortex, mRNA lev-
els of TNFα, IFNY, F4/80, CD68, MCP1 and IL-1RA were determined by qPCR using 36B4 as
a housekeeping gene.
(PDF)
S5 Fig. pGSK3/GSK3 ratio in BTBR-ob/ob mice. 12-week old female BTBR- ob/ob mice
received standard chow (Ctr) or chow with lithium supplementation (10 or 40 LiCl/kg). After
12 weeks kidneys were isolated and protein lysates were immunoblotted for pGSK3 and GSK3.
Representative immunoblots for ob/ob mice for (A) GSK3 and (B) pGSK3 are depicted. Corre-
sponding densitometric analysis of (C) total GSK3 abundance and pGSK3/GSK3 ratio
(n = 5–9 per group). Cm, Coomassie.
(PDF)
S1 Table. Primer sequences.
(PDF)
S2 Table. Blood glucose levels 30, 60 and 120 minutes after intraperitoneal glucose injec-
tion.
(PDF)
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